Quarterly report pursuant to Section 13 or 15(d)

LIQUIDITY (Details)

v3.23.1
LIQUIDITY (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2023
Jan. 31, 2022
Dec. 31, 2020
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2022
Mar. 10, 2023
Accumulated deficit       $ (248,257)   $ (248,257)   $ (209,198)  
Net loss       (15,672) $ (11,208) (39,059) $ (31,637) (41,100)  
Net cash used in operating activities           (33,131) (27,506) (39,600)  
Cash and cash equivalents, end of period       33,743 $ 63,416 33,743 $ 63,416 150,410  
Short-term investments in marketable debt securities       69,319   69,319      
Long-term investments in marketable debt securities       26,210   26,210      
Total liabilities       6,889   6,889   2,949  
Current liabilities       $ 4,387   4,387   $ 2,462  
Overnight Money Market Mutual Funds | Silicon Valley Bank Closure [Member]                  
Cash and cash equivalents, end of period                 $ 20,500
XOMA (US) LLC | Phase 3 Clinical Trial Rz 358 | Xoma License Agreement | Plan                  
Milestone closing payment   $ 5,000       $ 5,000      
ActiveSite Pharmaceuticals, Inc | Development And License Agreement                  
Milestone closing payment     $ 1,000            
ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement                  
Milestone closing payment $ 3,000